Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
100 hedge funds and large institutions have $82.1M invested in Paratek Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 32 reducing their positions, and 14 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 32
3% less funds holding
Funds holding: 103 → 100 (-3)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
27% less capital invested
Capital invested by funds: $113M → $82.1M (-$30.6M)
84% less call options, than puts
Call options by funds: $25K | Put options by funds: $160K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$3.98M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.01M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.08M |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$854K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$764K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.37M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$553K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$514K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$487K |
| 5 |
Two Sigma Advisers
New York
|
-$378K |
PRTK Hedge Fund Activity: Q1 2022 in Review
100 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2022, worth a combined $82.1M — down 27% from $113M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PRTK and 12 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 36 added.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $3.98M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $3.37M sold.
- 100 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2022, down from 103 in Q4 2021.
- Funds reported $82.1M of Paratek Pharmaceuticals, Inc. stock for Q1 2022, down 27% quarter-over-quarter.
- 12 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2022 and 14 closed out, a net change of -2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2022 was J. Goldman & Co, an estimated $3.98M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2022 was Granahan Investment Management, an estimated $3.37M sold.
Based on aggregated 13F filings for Q1 2022.